8 results about "Tumor suppressor gene" patented technology

The invention discloses an elephant source bacillus licheniformis and application thereof. The preservation number of the bacillus licheniformis strain L517 is GDMCC 67825, the bacillus licheniformis strain L517 is classified and named as bacillus licheniformis, and the preservation date is February 26, 2026. Research finds that the bacillus licheniformis has a remarkable treatment effect on acute colitis of mice; and the traditional Chinese medicine composition also has a remarkable treatment effect on mouse subcutaneous colon cancer. The anti-cancer mechanism is that the infiltration of GZMB < + > CD8 < + > cytotoxic T cells in a tumor microenvironment is remarkably promoted in vivo through a supernatant metabolite of a culture medium, and a tumor suppressor gene P53 can be directly up-regulated. It is found for the first time that the elephant intestinal tract source bacillus licheniformis with evolutionary disease-resistant advantages shows good anti-proctitis and colon cancer activity, and can become an effective medicine for treating proctitis and colon cancer in the future.

Provided are a method and a combination for one-tube simultaneous detection of tumor-specific gene mutation and methylation, and the use thereof. The method comprises searching a database to select mutation and methylation sites of a cancer driver gene and a cancer suppressor gene, synthesizing capture probes correspondingly paired with a target interval, performing hybrid capture on an amplification product of a sample treated with a restriction endonuclease by using a probe set comprising tumor-specific gene mutation and methylation capture probes, constructing a high-throughput sequencing library containing a target region, and performing high-throughput sequencing to obtain the sequence of a target fragment, so as to obtain the results of methylation, point mutations and indel variation of a cancer-associated gene. The provided method enables one-tube simultaneous detection of mutation and methylation states of a cancer-associated gene in one assay, requires a low content of a gene to be detected, can be used for methylation and mutation detection of a tumor-specific DNA, and has low detection costs and high efficiency.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. Disclosed herein are compounds and methods to recover wild-type function of p53 mutants using x-ray co-crystal structures of mutant p53 and compounds of the disclosure. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

The present disclosure relates to methods of treating pancreatic cancer. In particular, methods of treating pancreatic cancer and limiting overexpression of oncogenes, activating tumor suppressor genes, or modulating signaling proteins in a patient are described, comprising administering a compound and a pharmaceutical combination as described herein.

The present application relates to the technical field of biological diagnosis, and particularly relates to a mutant gene set for tumor molecular typing and application thereof, wherein the mutant gene set comprises 82 mutant genes including DNA methylation modification related genes, histone modification related genes, chromatin remodeling related genes, TCR signal pathway related genes, PI3K-AKT signal pathway related genes, JAK-STAT signal pathway related genes, immune escape related genes, P53 signal pathway related genes, tumor suppressor genes and NOTCH signal pathway related genes. The mutant gene set can be used for molecular typing, targeted therapy and overall survival prediction of intranodal peripheral T-cell lymphoma. The mutant gene set is verified by clinical trials, and is suitable for all primary and relapsed PTCL patients, relapsed or refractory peripheral T-cell lymphoma umbrella study based on genomics typing and PTCL patients receiving different treatment schemes, and has a very wide application range.

The invention provides a recombinant oncolytic adenovirus based on PCV2 functional protein as well as a preparation method and application of the recombinant oncolytic adenovirus, and belongs to the technical field of biological medicines. The genome of the recombinant oncolytic adenovirus based on the PCV2 functional protein provided by the invention comprises a PCV2 Cap gene and / or a PCV2 Rep gene. According to the invention, the Cap and / or Rep genes of PCV2 are / is taken as brand new therapeutic transgenosis, the recombinant oncolytic adenovirus is successfully constructed, and brand new candidate entities and action target bases different from traditional cell factors or tumor suppressor genes are provided for oncolytic virus therapy. According to the invention, the recombinant adenovirus is used as an efficient delivery vector, so that the transduction and expression efficiency of the PCV2 functional gene is greatly improved, and the limitations of low natural infection efficiency and weak replication ability of the PCV2 wild type virus are overcome. The recombinant oncolytic adenovirus, especially the recombinant Rep adenovirus, provided by the invention realizes a multi-mechanism synergistic efficient anti-tumor effect.

A method includes accessing a digital pathology image that depicts tumor cells sampled from a subject. A plurality of patches may be selected from the digital pathology image, wherein each of the patches depicts tumor cells. A mutation prediction may be generated for each of the patches, wherein the mutation prediction represents a prediction of a likelihood that an actionable mutation appears in the patch. Based on the plurality of mutation predictions, a prognostic prediction related to one or more treatment regimens for the subject may be generated. The prognostic prediction may be based on determining one or more mutational contexts of the digital pathology image as an unknown driver or a tumor suppressor, an oncogene driver mutation, or a gene fusion.

The invention discloses application of a pharmaceutical composition in preparation of a medicine for inhibiting liver cancer cell proliferation, and relates to the technical field of medicines. The pharmaceutical composition provided by the invention is a mixture of a flos carthami extract and a fructus gardeniae extract, wherein the mass ratio of the flos carthami extract to the fructus gardeniae extract is (1-2): (1-6). The safflower extract and the gardenia extract are found to be capable of remarkably inhibiting S100A6 protein expression, inhibiting hepatoma carcinoma cell Huh7 cell proliferation, inhibiting hepatoma carcinoma cell Huh7 cell cloning, inhibiting Huh7 cell proliferation genes, promoting expression of cancer suppressor genes, inhibiting Huh7 cell migration and inhibiting Huh7 cell invasion and migration related gene expression. New theoretical basis and experimental evidence are provided for application of traditional Chinese medicine in the field of liver cancer treatment, and an important guiding direction is provided for follow-up development of novel anti-liver cancer drugs based on flos carthami and fructus gardeniae.